Nature Commun:协助引起各种癌症的“帮凶”——TET2

2017-04-25 Heather_z727 medicalxpress

【科学家找到了刺激癌症形成的催化剂】想象一下这个场景:在高速公路上,司机突然想转向,然后意识到自己的错误,迅速转向,已经来不及了。其他司机们都来不及反应,因此开始发生碰撞。这一场景就好像各种血癌中TET2蛋白质的情况,TET2可以抑制肿瘤,阻止造血干细胞疯涨,然而,如果TET2发生突变,它还会引起其他基因突变,TET2的突变并不会直接致癌,但是却为癌症的形成创造了条件。研究人员表示:“如果你只是失


【科学家找到了刺激癌症形成的催化剂】想象一下这个场景:在高速公路上,司机突然想转向,然后意识到自己的错误,迅速转向,已经来不及了。其他司机们都来不及反应,因此开始发生碰撞。

这一场景就好像各种血癌中TET2蛋白质的情况,TET2可以抑制肿瘤,阻止造血干细胞疯涨,然而,如果TET2发生突变,它还会引起其他基因突变,TET2的突变并不会直接致癌,但是却为癌症的形成创造了条件。

研究人员表示:“如果你只是失去了TET2蛋白质,其实并没有什么严重的,然而可怕之处就在于,TET2蛋白质可以引发一系列的突变,导致各种类型的血癌。”

完整的研究报告发表于《自然》中,详细描述了TET2缺失如何导致引起骨髓癌,淋巴癌以及其他癌症基因突变的大门。

临床角度来说,解决TET2的问题比较棘手,TET2不是单独引起癌症的,而是由于TET2的缺失,无数基因突变与之配合,共同引起癌症。除此之外,靶向TET2蛋白质必须要趁早,一旦其他基因突变已经形成,再靶向TET2蛋白质,治疗效果则变得微乎其微了。

研究人员表示:“我们正在开发靶向TET2蛋白质的方法,如果我们可以在早期靶向TET2蛋白质,那么就可以成功的间将癌变的过程扼杀在摇篮里。”

原始出处:

Pan F, Wingo TS, Zhao Z, et al. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nature Communications. 2017 Apr 25.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011290, encodeId=c7d72011290ab, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Aug 14 10:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087001, encodeId=c352208e001b2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 04 02:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881954, encodeId=821d1881954b0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jan 01 22:30:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446527, encodeId=7389144652e34, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Thu Apr 27 10:30:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191000, encodeId=d11519100019, content=继续学习新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Apr 27 08:06:24 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-08-14 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011290, encodeId=c7d72011290ab, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Aug 14 10:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087001, encodeId=c352208e001b2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 04 02:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881954, encodeId=821d1881954b0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jan 01 22:30:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446527, encodeId=7389144652e34, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Thu Apr 27 10:30:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191000, encodeId=d11519100019, content=继续学习新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Apr 27 08:06:24 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2018-01-04 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011290, encodeId=c7d72011290ab, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Aug 14 10:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087001, encodeId=c352208e001b2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 04 02:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881954, encodeId=821d1881954b0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jan 01 22:30:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446527, encodeId=7389144652e34, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Thu Apr 27 10:30:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191000, encodeId=d11519100019, content=继续学习新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Apr 27 08:06:24 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2018-01-01 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011290, encodeId=c7d72011290ab, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Aug 14 10:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087001, encodeId=c352208e001b2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 04 02:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881954, encodeId=821d1881954b0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jan 01 22:30:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446527, encodeId=7389144652e34, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Thu Apr 27 10:30:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191000, encodeId=d11519100019, content=继续学习新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Apr 27 08:06:24 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 neurowu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2011290, encodeId=c7d72011290ab, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Aug 14 10:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087001, encodeId=c352208e001b2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 04 02:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881954, encodeId=821d1881954b0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jan 01 22:30:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446527, encodeId=7389144652e34, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Thu Apr 27 10:30:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191000, encodeId=d11519100019, content=继续学习新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Apr 27 08:06:24 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 doctorJiangchao

    继续学习新机制

    0

相关资讯

重磅文章解读超声技术治疗癌症等疾病的进展

近年来,随着超声分子影像技术的发展以及在临床中的应用,科学家们已经能够利用超声分子技术为患者提更加精准的诊疗了。如今超声医学已经突破了传统超声显像诊断领域的限制,迈入了“纳米”时代。而且研究人员也开发出了更加新型的超声技术,能够敏感地发现实质性脏器内常规影像检查无法发现的转移性癌症病灶,并在超声波的介导下,传递和释放靶向抗癌药物,精准地杀死癌细胞。 那么近年来科学家们利用超声技术在诊

科学家如何深度破解癌症基因组的奥秘?

此前,国际癌症基因组联盟(International Cancer Genome Consortium)向科学界公布了超过1万个癌症基因组的数据,利用这些数据科学家们就能够更好地从基因方面入手来了解癌症的发生及进展机制,这就为后期研究人员开发治疗多种癌症的新型靶向疗法提供了新的思路。 近年来,科学家们一直在深入进行癌症基因组学等相关研究,他们希望通过深入剖析能够鉴别出引发癌症的根本原

Cell:研究揭秘癌症治疗的新突破口!

【肠道细菌如何改变抗癌药物活性的】根据UCL主导的关于线虫和其微生物如何处理药物和营养物质的研究,癌症药物的活性取决于生活在肠道中的微生物的类型。该发现突出显示了控制肠细菌和饮食以改善癌症治疗的潜在益处,以及了解药物有效性为何在个体之间变化。这项由Cell出版,由Wellcome皇家学会和医学研究委员会资助的研究,报告了一种新的高通量筛选方法,揭示宿主生物体肠道微生物与药物作用之间的复杂关

缺氧真的是导致癌细胞不断肆虐的元凶?

1955年,研究者Thomlinson等人在对来自肺癌患者的肿瘤组织进行研究时首次提出肿瘤缺氧的观点,随后科学家们经过60多年临床和实验证实,缺氧状态是多种实体瘤中广泛存在的一种特质,而且缺氧这种特征与肿瘤的增殖、分化、血管生成、能量代谢以及癌症的耐药性发生、患者预后较差密切相关。 很多研究人员认为缺氧是癌细胞不断得以繁衍的一个关键因素,而且缺氧还会让肿瘤细胞的恶性程度不断增加,近日

深度解读如何跨越血脑屏障来攻克人类疾病

血脑屏障(blood–brain barrier),是一种大脑血管(微血管)、细胞以及其它组成大脑组织之间的保护性屏障;其能够为大脑提供一种防御机制来抵御血液中存在的诱发疾病的病原体和毒素等。 19世纪末,当德国研究者Paul Ehrlich将一种染料注射到小鼠血流中时,他发现了血脑屏障,让他非常惊讶的是,除了大脑和脊髓外,这种染料能够进入几乎小鼠机体所有的组织,研究者认为大脑和血液

新型成像技术或将不断推进癌症深入研究

随着癌症筛查工具的不断涌现,新型的癌症成像技术也给科学家们在癌症诊断及判断患者对药物的反应等相关领域带来了极大帮助,当然这对于改善癌症患者未来的治疗或许意义深远。基于强大的癌症成像技术,研究人员就能够更加快速地发现患者机体中的癌症;同时也能够对癌细胞的一举一动进行实时监测,当然有些成像技术也能够帮助研究者预测患者对癌症药物应答。 那么近年来,新型癌症成像技术到底是如何促进科学家们在癌